Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
Yasuhiko Yamamoto, … , Hiroshi Okamoto, Hiroshi Yamamoto
Yasuhiko Yamamoto, … , Hiroshi Okamoto, Hiroshi Yamamoto
Published July 15, 2001
Citation Information: J Clin Invest. 2001;108(2):261-268. https://doi.org/10.1172/JCI11771.
View: Text | PDF
Article

Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

Abstract

Vascular complications arising from multiple environmental and genetic factors are responsible for many of the disabilities and short life expectancy associated with diabetes mellitus. Here we provide the first direct in vivo evidence that interactions between advanced glycation end products (AGEs; nonenzymatically glycosylated protein derivatives formed during prolonged hyperglycemic exposure) and their receptor, RAGE, lead to diabetic vascular derangement. We created transgenic mice that overexpress human RAGE in vascular cells and crossbred them with another transgenic line that develops insulin-dependent diabetes shortly after birth. The resultant double transgenic mice exhibited increased hemoglobin A1c and serum AGE levels, as did the diabetic controls. The double transgenic mice demonstrated enlargement of the kidney, glomerular hypertrophy, increased albuminuria, mesangial expansion, advanced glomerulosclerosis, and increased serum creatinine compared with diabetic littermates lacking the RAGE transgene. To our knowledge, the development of this double transgenic mouse provides the first animal model that exhibits the renal changes seen in humans. Furthermore, the phenotypes of advanced diabetic nephropathy were prevented by administering an AGE inhibitor, (±)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195), thus establishing the AGE-RAGE system as a promising target for overcoming this aspect of diabetic pathogenesis.

Authors

Yasuhiko Yamamoto, Ichiro Kato, Toshio Doi, Hideto Yonekura, Seiji Ohashi, Masayoshi Takeuchi, Takuo Watanabe, Sho-ichi Yamagishi, Shigeru Sakurai, Shin Takasawa, Hiroshi Okamoto, Hiroshi Yamamoto

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Generation and characterization of RAGE transgenic mice. (a) Transgene c...
Generation and characterization of RAGE transgenic mice. (a) Transgene construct. The human RAGE genomic sequence, beginning with the initiator codon in exon 1 and ending 129 bp downstream from the last exon, was placed under the transcriptional control of the murine flk-1 promoter. The flk-1 fragment encompassed the 5′ untranslated region (dark gray box), sharing the ATG codon with the RAGE fragment. (b) Transgene-derived transcripts. Total RNAs isolated from various tissues of line 102 and 103 heterozygotes were analyzed by RT-PCR. The granulation tissue — the focus of angiogenesis — was prepared by punching out an area of the dorsal skin about 4–5 mm in diameter. The PCR-amplified products had a chain length of 354 bp as predicted and were sequence-verified. (c) Immunofluorescence staining of kidneys from line 102 RAGETg or nontransgenic control at 4 months of age using anti-human RAGE-specific polyclonal Ab. Original magnification, ×430. (d) Translation products of the transgene. Extracts of isolated ECs from renal cortex or peripheral blood monocytes of line 102 RAGETg or the nontransgenic control were immunodetected with the human RAGE Ab. Specific bands were marked at 55 kDa in line 102 RAGETg EC and monocyte extracts. VE-cad, VE-cadherin, i.e., an EC marker; CD14, a monocyte marker.